[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

**Original Article**

**Ultrasonographic Intravesical Prostatic Protrusion in Men with Benign Prostatic Hyperplasia in Southwest Nigeria**



**Abstract**

**Objectives:** To study the relationship between sonographically measured intravesical prostate protrusion and international prostate symptoms score (IPSS), as well as prostate volume, in men with benign prostatic hyperplasia at a single health facility. **Materials and Methods:**This was a cross-sectional observational study of one hundred men (age >40 years) diagnosed with benign prostatic hyperplasia. Their International Prostate Symptoms Score (IPSS) was assessed using the standardised IPSS instrument. Abdominal ultrasound was done to measure the intravesical prostatic protrusion (IPP), while prostate volume was estimated transabdominally and transrectally. Correlations between parameters were quantified with Spearman’s correlation test. P ≤ 0.05 was statistically significant. **Results:** The mean age was 62.84±9.0 years (Range =42–79 years). The mean IPSS was 20.99±6.42 (range of 5–30). Seventy-three percent of the men in this study had intravesical prostatic protrusion on ultrasound. The mean IPP was 13.0±4.0mm. Of the 73 men with IPP, 17 (23.3%), 29 (39.7%), and 27 (37%) had grade I, grade II and grade III IPP, respectively. The mean transabdominal prostate volume (TPVA) and transrectal prostate volume (TPVT) were 71±14ml and 69±13ml, respectively. IPP had a statistically significant positive correlation with all the other parameters. The strongest correlation (very high correlation) was with the TPVA (r=0.797, *P* < 0.0001), followed by a moderate correlation with the IPSS (r =0.513, *P* < 0.0001). TPVT, transition zone volume, transition zone index, presumed circle area ratio, and quality of life score yielded slightly weaker moderate correlation with IPP, while IPP correlated weakly with age. **Conclusion:** IPP correlated well with multiple clinical and sonographic parameters. It correlated better with TPVA than TPVT.

**Keywords:** *Benign prostatic hyperplasia, international prostate symptom score, intravesical prostate protrusion, lower urinary tract symptoms, prostate volume, ultrasound*

**Tolulope Adebayo Okedere, Bukunmi Michael Idowu1,**

**Stephen Olaoluwa Onigbinde2**

*Department of Radiology,Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria, 1Department of Radiology, Union Diagnostics and Clinical Services Plc, Yaba, Lagos State, Nigeria, 2Department of Anatomical Sciences, School of Medicine,*

*St George’s University, Grenada*

**Introduction**

Recently, clinical benign prostatic hyperplasia (BPH) has been defined as prostatic adenoma(ta) causing a spectrum of bladder outlet obstruction which might eventually impair renal and vesical excretory functions.[1,2]

Male lower urinary tract symptoms (LUTS) could present with obstructive or voiding symptoms (diminished urine stream, dysuria, hesitancy, terminal dribbling, reduced urine stream, splitting urine stream, straining to void, and intermittency), irritative or storage symptoms (urgency, urge incontinence, frequency, nocturia), and post-micturition symptoms (sensation of incomplete voiding, post-micturition dribbling). Benign prostatic hyperplasia, urethral stricture, and prostatic carcinoma are the leading causes

This is an open access journal, and articles are distributed under the terms ofthe Creative CommonsAttribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** reprints@medknow.com

of LUTS.[3-5] The International Prostate Symptoms Score (IPSS), Iversen score, Madsen score, Boyarsky score, and Danish prostatic symptom score are validated for assessing the severity of lower urinary tract symptoms, but the IPSS is the preferred instrument in men.[6]

There were 94 million prevalent cases of benign prostatic hyperplasia worldwide in 2019, which represents a 70.5% increase compared to the 51·1 million cases in the year 2000.[7] Globally, the disease burden of BPH is greater than that of all other male genitourinary disorders put together. The prevalence of BPH over a person’s lifetime ranges from 22.8 to 29.6%.[8]

In Nigeria, there were 305,000 (range = 224,000 – 413,000) cases in the year 2000, which had increased by 36.3% (33.3 - 40.4%) to 415,000 (range = 308,000 – 566,000) cases by 2019.[7] Local community-

**How to cite this article:** Okedere TA, Idowu BM, Onigbinde SO.ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria. J West Afr Coll Surg 2023;13: 16-22.

**Received:** 31-Oct-2022 **Accepted:** 22-Nov-2022 **Published:** 20-Mar-2023

***Address for correspondence:*** *Dr. Bukunmi Michael Idowu, Department of Radiology, Union Diagnostics and Clinical*

*Services Plc, Yaba, Lagos State, Nigeria.*

*E-mail: ibmcontacts@gmail.com*

**Access this article online**

**Website:**

www.jwacs-jcoac.com

**DOI:** 10.4103/jwas.jwas\_270\_22

**Quick Response Code:**

16 © 2023 Journal of the West African College of Surgeons | Published by Wolters Kluwer ‑ Medknow

[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

Okedere, *et al.*: Ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria

based studies yielded a BPH prevalence of 23.7% - 25.3%,[9] while hospital-based studies reported a much high prevalence rate of 71.3% - 92%.[10,11] Approximately 27% of all cases of obstructive uropathy in our environment are attributable to BPH.[12] The predisposing factors for BPH include non-modifiable (Age, family history, Black race) and modifiable (Obesity, cardiovascular diseases, sedentary lifestyle, type 2 diabetes mellitus, dyslipidemia, hormonal imbalance, etc.) risk factors.[13,14]

With the refined definition mentioned above, clinical benign prostatic hyperplasia is now easier to discriminate from other less common aetiologies of male lower urinary tract symptoms (LUTS) using relatively simple and non-invasive transabdominal sonographic parameters: intravesical prostatic protrusion and prostate volume.[1,2]

The sonographically visible intravesical prostate protrusion (IPP) is caused by the enlargement of the median and or lateral lobes of the prostate gland into the urinary bladder neck.[15,16] This prostatic protrusion results in a “ball-valve” type of obstruction, which is worsened by subsequent forceful bladder contractions.[15] The IPP is measured on a midline longitudinal/sagittal view of a comfortably full bladder (about 200ml) as the perpendicular distance (in millimeters) between the innermost intravesical protrusion of the prostate (prostatic tip) and the bladder neck.[1] IPP has a 100% specificity and 100% positive predictive value for diagnosing prostate adenoma.[1] It also correlates strongly with bladder outlet obstruction index measured by pressure flow studies.[6]

Maximum intravesical prostate protrusion (IPP) is obtained when the urinary bladder is comfortably distended, as stated above, with an inverse relationship between intravesical prostate protrusion and increasing urinary bladder volume beyond 200ml.[17]

The purpose of this study was to assess the prevalence of IPP in men with BPH-related lower urinary tract symptoms and to determine its relationship with the International Prostate Symptoms Score (IPSS), transabdominal ultrasound prostatic volume, and transrectal ultrasound prostate parameters.

**Materials and Methods**

This prospective, descriptive cross-sectional study was conducted on 100 men, aged 40–90 years, with diagnosis of BPH by the Urologist, who were enrolled consecutively from the Urology clinic of the Obafemi Awolowo University teaching hospitals complex, Ile-Ife, Osun State, Nigeria. The study was approved by the Ethics and Research Committee of the hospital. Written informed consent was obtained from all the participants.

The study included individuals who were diagnosed with BPH based on clinical history of LUTS, digital rectal examination, prostate specific antigen <4ng/ml, and

transabdominal prostatic volume >30ml (or grams or cm3). Patients with the following conditions were excluded from the study: prostate or bladder cancer, prostatitis, in-dwelling catheter, bladder calculi, urethral stricture, neurogenic bladder, acute urinary retention, history of transurethral resection of the prostate or previous urinary tract surgery, and anal stenosis or previous extensive rectal surgery.

The age, weight, height, body mass index (BMI), and PSA values of the participants were recorded. International Prostatic Symptoms Score and quality of life score were assessed using the standardized IPSS questionnaire. The IPSS is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the symptoms. The answers are assigned points from 0 to 5. The total score ranges from 0 - 35 (i.e., asymptomatic to very symptomatic) and the symptoms stratified into Mild (symptom score < 7), Moderate (symptom score = 8–19), Severe (symptom score = 20–35).[18]


The sonographic measurements were carried out with a Mindray® model DC-7 ultrasound machine (Shenzhen Mindray Bio-medical Electronics, Nanshan, Shenzhen, China). A transrectal biplanar transducer (frequency = 5.0 – 10.0 MHz) was used for transrectal scan of the prostate gland, while a curvilinear transducer (frequency = 3.5 – 5.0 MHz) was used for the transabdominal ultrasound scan of the prostate.

Transabdominal (100–200ml of urine to measure IPP, then full bladder for TPVA) and transrectal (with empty bladder) prostate ultrasonography were performed in accordance with previously described standard techniques.[8,19,20] The urine volume was calculated on orthogonal views of the urinary bladder using the prolate ellipsoid formula: Volume (ml) = superior-inferior length (height) x anteroposterior (depth) x transverse (width) diameters.[21,22]

The longitudinal diameter (LD), anteroposterior diameter (APD), and transverse diameter (TD) of the prostate were measured. The transabdominal total prostate volume (TPVA) at full bladder volume, transrectal total prostate volume (TPVT), and the transition zone volume (TZV) were calculated using ellipsoid formula (0.523 x LD x APD x TD). The transitional zone index (TZI = TZV/ TPVT) and the presumed circle area ratio (PCAR) were also calculated.[8,19]

On transabdominal ultrasound, the intravesical prostatic protrusion (IPP) was measured with 100–200ml of urine in the bladder. A midline longitudinal/sagittal image of the urinary bladder neck and the prostate was obtained. In those with protruding median lobe, the IPP was measured (in millimeters) from the protruding prostatic tip to the to the circumference of the urinary bladder at the base of the

Journal of the West African College of Surgeons | Volume 13 | Issue 2 | April‑June 2023 17

[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

Okedere, *et al.*: Ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria

prostate gland [Figure 1]. The IPP was graded as follows: Grade I: < 5mm; Grade II: 5 -10mm; Grade III: > 10mm.[6]

The examinations were carried out by the same investigator to eliminate inter-observer variability. All sonographic measurements were taken thrice and the mean values were recorded for each subject, to ensure accuracy of the measurements and reduce intra-observer variation.

The data obtained were analysed using the IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, N.Y., USA). Data Normality was tested with the Kolmogorov-Smirnov’s test. Continuous variables were presented as mean ±Standard deviation (SD) and ranges, while categorical variables were presented as frequencies and proportions. The relationship between variables was tested using Spearman’s correlation for non-parametric data. The strength of the correlation coefficients was grade as follows: r = 0 – 0.2: very low/negligible and probably meaningless correlation; r = >0.2 – 0.4: low correlation; r = >0.4 – 0.6: moderate correlation; r = >0.6 – 0.8: high correlation; r = >0.8 – 1.0: excellent/very high correlation.[23] At 95% confidence interval, *P* values ≤ 0.05 was considered statistically significant.

**Results**



A total of 100 men with BPH were studied. Their mean age was 62.84±9.0 years (Range = 42–79 years) [Table 1]. The age subgroups were as follows: 40–49 years (10; 10%), 50–59 years (26; 26%), 60–69 years (36; 36%), and 70–79 years (28; 28%).

volume was 69±13ml (range = 46–96ml). The summary statistics of the other variables are shown in [Table 1].

The mean IPSS of all the participants was 20.99±6.42 (range = 5 – 30). Mild, moderate, and severe IPSS were recorded in 10 (10%), 31 (31%), and 59 (59%) participants, respectively [Table 2]. Furthermore, the mean IPSS by age group were 14±6.6 (40–49 years), 21±6.0 (50–59 years),

**Table 1: Clinical and sonographic characteristics of the study population**

**Parameters** **Mean± SD** **Range** Age (Years) 62±9.0 42–79 TPVT (ml) 69±13 46–96 TZV (ml) 54±15 29–83 TPVA (ml) 71±14 48–97 TZI 0.8±0.1 0.6–0.9 IPP (mm) 13.0±4.0 10.0–20.0 PCAR 0.8±0.7 0.6–0.9 QOLS 3.7±0.8 2.0–5.0

IPP=Intravesical Prostatic Protrusion; PCAR=Presumed Circle Area; QOLS=Quality of Life Score; TPVA=Transabdominal Total Prostate Volume; TPVT=Transrectal Total Prostate Volume; TZI=Transition Zone Index; TZV=Transition Zone Volume

**Table 2: International prostate symptoms scores (IPSS) of the participants**

**Symptoms** **Frequency** **Percentage** Mild 10 10 Moderate 31 31

The mean transabdominal total prostate volume was 71±14ml Severe 59 59 (range = 48–97ml), while the mean transrectal total prostate Total 100 100

**Figure 1: Transabdominal ultrasound measurement of Intravesical Prostatic Protrusion in two different men with benign prostatic hyperplasia as the distance between the tip of the prostate’s protrusion into the bladder and the bladder neck**

18 Journal of the West African College of Surgeons | Volume 13 | Issue 2 | April‑June 2023

[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

Okedere, *et al.*: Ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria

**Table 3: Clinical and Ultrasound parameters by age group**

**Parameters IPP (mm) TPV (ml) TPVT (ml) TZI PCAR IPSS QOLS TPVA (ml)**

**40-49 (N=10)** 16.0±5.0

60±10 43±11 0.7±0.1 0.7±0.1 14±6.6 3.2±0.6 62±11

**50-59 (N=26)** 13.0±5.0

60±10 43±11 0.7±0.1 0.8±0.1 21±6.0 3.7±0.7 71±14

**60-69 (N=36)** 12.0±4.0

67±15 52±15 0.7±0.1 0.8±0.1 20±5.8 3.7±0.7 68±15

**70-79 (N=28) t *P* value** 11±4.0 8.001 **0.046** 77±9.0 14.441 **0.002** 61±10 14.197 **0.003** 0.8±0.0 13.359 **0.004** 0.8±0.1 10.220 **0.017** 24±5.7 18.331 **0.005** 4.0±0.9 7.575 **<0.001** 78±9.6 12.685 **0.002**

t= Kruskal Wallis test statistics

IPP=Intravesical Prostatic Protrusion; PCAR=Presumed Circle Area; QOLS=Quality of Life Score; TPVA=Transabdominal Total Prostate Volume; TPVT=Transrectal Total Prostate Volume; TZI=Transition Zone Index; TZV=Transition Zone Volume

**Table 4: Intravesical Prostatic Protrusion (IPP) grades in the study population**

**Grade** **Frequency** **Percent** I 17 23.3% II 29 39.7% III 27 37.0% Total 73 100

20±5.8 (60–69 years), and 24±5.7 (70–79 years) [Table 3]. [Table 3] shows the summary statistics of the other variables by age group.

Intravesical prostate protrusion (IPP) was seen in 73 (73%) men. Of these 73, 17 (23.3%), 29 (39.7%), and 27 (37%) had grade I, grade II, and grade III IPP, respectively [Table 4]. The IPP distance ranged from 10mm to 20mm, with a mean of 13.0±4.0mm [Table 1].

In [Table 5], the mean age of the 29 participants with grade II IPP (67±9.1 years) was significantly higher than that of men with grade III IPP (64±8.6 years), while those with grade III IPP also had a significantly higher mean age than the grade I IPP subgroup (60±6.5 years). Moreover, the grade II IPP subgroup had the highest IPSS, TPVT, TPVA, and QOLS. In contrast, the grade III IPP subgroup had the highest TZV. Grade II IPP and grade III IPP subgroups had essentially the same TZI and PCAR [Table 5].

[Table 6] shows the relationship between intravesical prostate protrusion (IPP) and other evaluated parameters. IPP had a statistically significant positive correlation with all the other parameters. The strongest correlation (very high correlation) was with the transabdominal total prostate volume (r = 0.797, *P*<0.0001), followed by a moderate correlation with the IPSS (r=0.513,*P*<0.0001). TPVT, TZV, TZI, QOLS, and PCAR yielded marginally weaker moderate correlation with IPP. IPP correlated weakly with age.

**Discussion**

Intravesical prostatic protrusion (IPP) has been investigated for multiple potential uses in urology. These include, interalia, diagnosis of bladder outlet obstruction, predictor of trial without catheter (TWOC), predictor of medical

treatment effect, predictor of progression of BPH-related LUTS, is a risk factor for bladder stone in BPH, predictor of overactive bladder, predictor of prostate carcinoma, and predictor of early urinary continence recovery after laparoscopic radical prostatectomy.[24]

Ultrasonographic assessment of intravesical prostate protrusion (IPP) now plays an important role in the diagnosis of BPH. Multiple studies have shown that IPP, taken together with transabdominal total prostate volume (TPVA), correlates well with benign prostatic obstruction and the progression of the disease.[1,2,25-27]

The mean age of the study population was 62.84±9.0 years. The seventh decade of life was also the mean age of subjects with BPH in multiple previous studies in this environment and elsewhere. Hamza*etal.* (63.7years ± 8.9years),[6] Agbo *et al.* (64.6±10.2 years),[28] Aigbe *et al.* (68.12±9 years),[29] Obiesie *et al.* (69.3 ± 10.6 years),[20] Mbouche *et al.* (63.17±10.26 years),[30] Galeti *et al.* (65.94±8.27 years),[31] and Tchaou *et al.* (66.63±11.55 years)[32] documented mean age in the same range in Kaduna, Jos, Irrua, Nnewi, Cameroon, India, and Togo, respectively. The seventh decade of life coincides with the period of symptomatic benign prostatic enlargement following hyperplasia of the prostatic stroma.[3] The onset of BPH can occur as early as 25–30 years of age. The prevalence of histologically detectable BPH increases with age, such that by the sixth decade (age 51 to 60 years), it exceeds fifty percent.[33,34]

The mean IPP in this study was 13.0±4.0mm which lies within grade III IPP. This is similar to the findings of Hamza *et al.*,[6] Agbo *et al.*,[28] Oshagbemi *et al.*,[35] and Sigdel *et al.*[36] who reported mean IPP of 10.3mm, 12.9mm, 13.04mm, and 14.6mm, respectively. In contrast, the mean IPP of the study by Gopinath *et al.* (9.81±5.1mm)[37] and Galeti *et al.* (9.81±5.41mm)[31] which fell in the grade II IPP range. Differences in the severity of prostatic median and or lateral lobe enlargement in the subjects recruited is likely responsible for this disparity.

Seventy-three (73%) of the 100 subjects showed intravesical prostate protrusion (IPP) on ultrasound, while 27 (27%) had enlarged prostate glands without IPP. In the study by

Journal of the West African College of Surgeons | Volume 13 | Issue 2 | April‑June 2023 19

[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

Okedere, *et al.*: Ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria

**Table 5: Clinical and ultrasound parameters compared by IPP grade**

**Parameters**

Age (years) IPSS TPVT (ml) TZV (ml) TZI PCAR QOLS TPVA (ml)

**IPP Grade I (N= 17)**

60±6.5 18±6.9 62±12 44±13 0.7±0.1 0.7±0.1 3.6±0.5 62±11

**IPP Grade II (N=29)**

67±9.1 25±2.7 79±11 64±11 0.8±0.0 0.8±0.0 4.3±0.7 81±12

**IPP Grade III** **df (N=27)**

64±8.6 2 23±5.5 2 73±13 2 83±58 2 0.8±0.1 2 0.8±0.1 2 3.9±0.7 2 74±13 2

**t** ***P* value**

9.088 **0.011** 19.838 **<0.0001** 18.767 **<0.0001** 21.575 **<0.0001** 25.619 **<0.0001** 23.696 **<0.0001** 9.133 **0.010** 21.093 **<0.0001**

IPP=Intravesical Prostatic Protrusion; PCAR=Presumed Circle Area; QOLS=Quality of Life Score; TPVA=Transabdominal Total Prostate Volume; TPVT=Transrectal Total Prostate Volume; TZI=Transition Zone Index; TZV=Transition Zone Volume

t= Kruskal Wallis test statistics

**Table 6: Correlation between intravesical prostatic protrusion and other test parameters**

**Parameters** **r** ***P* value** Age (years) -0.282 **0.005** IPSS -0.513 **<0.0001** TPVT (ml) -0.458 **<0.0001** TZV (ml) -0.453 **<0.0001** TZI -0.430 **<0.0001** QOLS -0.487 **<0.0001** PCAR -0.375 **<0.0001** TPVA (ml) -0.797 **<0.0001**



r = Spearman’s correlation coefficient

IPP=Intravesical Prostatic Protrusion; PCAR=Presumed Circle Area; QOLS=Quality of Life Score; TPVA=Transabdominal Total Prostate Volume; TPVT=Transrectal Total Prostate Volume; TZI=Transition Zone Index; TZV=Transition Zone Volume

Gopinath *et al.*,[37] intravesical prostatic protrusion was present in 42.6% of patients. Of the 73 men with IPP in this study, 17 (23.3%), 29 (39.7%), and 27 (37%) had grade I, grade II and grade III IPP, respectively. In comparison, the percentages of patients with grade I, grade II and grade III IPP, respectively, were 28.2%, 24.4% and 47.4% by Oshagbemi *et al.*[35]; 7.9%, 32.7%, 59.4% by Eze *et al.*[38]; and 37.1%, 12.6%, 50.3% by Hamza *et al.*[6] The tally of the IPP subgroups differ between studies possibly because of the differences in the age, prostate volume, and median/lateral lobe enlargement of the recruited subjects. Furthermore, in the index study, a whopping 27 participants had BPH without IPP.

In this study, IPP had a statistically significant positive correlation with all the evaluated parameters. The strongest correlation (very high correlation) was with the transabdominal total prostate volume (r = 0.797, *P*<0.0001), followed by a moderate correlation with the IPSS (r = 0.513, *P*<0.0001). TPVT, TZV, TZI, QOLS, and PCAR yielded marginally weaker moderate correlation with IPP, while IPP correlated weakly with age. Similarly, other researchers reported significant correlations between

IPP and multiple parameters; for example, Eze *et al.* (IPSS),[38] Gopinath *et al.* (TPVA),[37] Sigdel *et al.* (IPSS, TPVA, maximum flow rate, postvoid residual urine volume, PVR),[36] Hamza *et al.* (IPSS, Quality of life (QoL) score, PVR),[6] Shrestha *et al.* (IPSS, QoL score),[39] Wang *et al.* (TPVA, maximum flow rate),[40] Reddy *et al.* (TPVA, bladder outlet obstruction index),[41] and Lee *et al.* (TPVA, bladder outlet obstruction index).[42] The variability in various correlations with IPP could stem from lack of strict compliance with the urine volume at which IPP should be measured which eventually affects the grading of IPP and interobserver variability in studies that used more than one sonologist (including retrospective studies). IPP correlated better with transabdominal total prostate volume than transrectal total prostate volume likely because of the relatively narrow range of urine volume (100–200ml) at which IPP is maximal, such that TPVA (measured at full bladder volume) and TPVT (measured with completely empty bladder) should expectedly diverge from the IPP minimally and moderately, respectively.

The limitations of this study include its hospital-based nature using a relatively small sample size. Furthermore, the cross-sectional study design makes to impossible to establish or debunk a direct causal relationship between BPH-related LUTS and IPP. Finally, we could not correlate IPP with uroflowmetry findings because the equipment was unavailable at the time of this study.

In conclusion, 73% of the men in this study had intravesical prostatic protrusion on ultrasound. IPP correlated with positively with TPVA, IPSS, TPVT, TZV, TZI, QOLS, and PCAR. IPP correlated better with transabdominal total prostate volume than transrectal total prostate volume.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

20 Journal of the West African College of Surgeons | Volume 13 | Issue 2 | April‑June 2023

[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

Okedere, *et al.*: Ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria

**References**

1. Foo KT. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol 2019;37:1293-6.

2. Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol 2017;4:152-7.

3. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: Epidemiology, economics and evaluation. Can J Urol 2015;22 Suppl 1:1-6.

4. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 2005;7 Suppl 7:S3-S11.

5. Idowu BM. Prostate carcinoma presenting with diffuse osteolytic metastases and supraclavicular lymphadenopathy mimicking multiple myeloma. Clin Case Rep 2018;6:253-7.

6. Hamza BK, Ahmed M, Bello A, Tolani MA, Awaisu M, Lawal AT, *et al*. Correlation of intravesical prostatic protrusion with severity of lower urinary symptoms among patients with benign prostatic hyperplasia. Afr J Urol 2021;27:4.

7. Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, *et al*. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the global burden of disease study 2019. Lancet Healthy Longev 2022;3:e754-76.

8. Onigbinde SO, Asaleye CM, Salako AA, Idowu BM, Onigbinde AO, Laoye A. The effect of systemic hypertension on prostatic artery resistive indices in patients with benign prostate enlargement. Prostate Int 2022 In Press. DOI: 10.1016/j. prnil.2022.09.001.

9. Ojewola RW, Oridota ES, Balogun OS, Alabi TO, Ajayi AI, Olajide TA, *et al*. Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a South-Western Nigerian rural setting: A cross-sectional study. Afr J Urol 2017;23:109-15.

10. Bock-Omma A, Dienye P, Oghu I. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care, Port Harcourt, Nigeria. South Afr Fam Pract 2013;55:467-72.

11. Olapade-Olaopa EO, Owoaje ET, Ladipo MM, Fadimu OA, Muoka O, Adedeji TG. Frequency and pattern of lower urinary tract symptoms in a screened population of men above 40 years in ibadan, southwestern Nigeria. J West Afr Coll Surg 2015;5:60-78.

12. Apoku IN, Ayoola OO, Salako AA, Idowu BM. Ultrasound evaluation of obstructive uropathy and its hemodynamic responses in southwest Nigeria. Int Braz J Urol 2015;41:556-61.

13. Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male 2019;22:12-9.

14. Yeboah ED. Prevalence of benign prostatic hyperplasia and prostate cancer in africans and africans in the diaspora. J West Afr Coll Surg 2016;6:1-30.

15. Gyawali P, Shrestha G, Shrestha JB, Chalise P, Sharma U. Intravesical prostatic protrusion is better than prostate volume in predicting symptom severity in benign prostatic hyperplasia: A prospective clinical study. Post-Grad Med J NAMS 2010;10:24-8.

16. Reis LO, Barreiro GC, Baracat J, Prudente A, D’Ancona CA. Intravesical protrusion of the prostate as a predictive method of bladder outlet obstruction. Int Braz J Urol 2008;34:627-33; discussion 634–7.

17. Yuen JS, Ngiap JT, Cheng CW, Foo KT. Effects of bladder volume

on transabdominal ultrasound measurements of intravesical

prostatic protrusion and volume. Int J Urol 2002;9:225-9.

18. Oruqi M, Podvorica E, Islamaj J. The self-administered international prostate symptoms score (IPSS) questionnaire of kosovo men with benign prostatic hyperplasia. Open J Urol 2021;11:367-79.

19. Fanimi OO, Asaleye CM, Salako AA, Ayoola OO, Adedeji TA, Idowu BM. Transrectal doppler sonography of benign prostatic enlargement in nigerian men. J Med Ultrasound 2019;27:169-76.

20. Obiesie AE, E Nwofor AM, Oranusi CK, Mbonu OO. Correlation between prostate volume measured by ultrasound and symptoms severity score in patients with benign prostatic hypertrophy in southeastern Nigeria. Niger J Clin Pract 2022;25:1279-86.

21. Hvarness H, Skjoldbye B, Jakobsen H. Urinary bladder volume measurements: Comparison of three ultrasound calculation methods. Scand J Urol Nephrol 2002;36:177-81.

22. Dicuio M, Pomara G, Menchini Fabris F, Ales V, Dahlstrand C, Morelli G. Measurements of urinary bladder volume: Comparison of five ultrasound calculation methods in volunteers. Arch Ital Urol Androl 2005;77:60-2.

23. Harris M, Taylor G. Medical statistics made easy 3. 3rd ed. Banbury, UK: Scion; 2014.

24. Mehraban D. Clinical value of intravesical prostatic protrusion in the evaluation and management of prostatic and other lower urinary tract diseases. Asian J Urol 2017;4:174-80.

25. Raphael JE, Abhulimen V. Is there any relationship between total prostate volume, intravesical prostatic protrusion and lower urinary tract symptoms in adult nigerian men with benign prostatic enlargement? West Afr J Med 2021;38:578-82.

26. Rieken M, Presicce F, Autorino R, DE Nunzio C. Clinical significance of intravesical prostatic protrusion in the management of benign prostatic enlargement: A systematic review and critical analysis of current evidence. Minerva Urol Nefrol 2017;69:548-55.

27. Eze BU, Amu OC, Edeh JA. A Review of Intravesical Prostatic Protrusion in the Evaluation and Treatment of Benign Prostatic Enlargement. Eur J Med Health Sci 2021;3:13-7.

28. Agbo CA, Ramyil VM, Dakum NK, Shuaibu SI, Onowa VE, Nabasu LE, *et al*. The value of intravesical prostatic protrusion in evaluation of bladder outlet obstruction from benign prostatic enlargement in Nigeria. Afr J Urol 2018;24:342-6.

29. Aigbe E, Ogbetere FE. Relationship between prostate volume, age and body mass index among patients with benign prostatic hyperplasia in the Niger Delta region, Nigeria. Afr Urol 2022;2:32-4.

30. Mbouché LO, Mbassi AA, Ngallè FGE, Ako F, Makon ASN, Moifo B, *et al*. Correlation between the International Prostate Symptom Score, Ultrasound Features and Maximum Flow Rate in Cameroonian Patients with Benign Prostatic Hypertrophy. Open J Urol 2022;12:37-50.

31. Galeti EH, Rasool M, Bharali MD. Intravesical prostatic protrusion and prostate volume in patients with acute urine retention. Int Surg J 2022;9:356-61.

32. Tchaou M, Hounkpevi JM, Gbande P, Padja E, Kpatcha T, Gbadoe E, *et al*. Intravesical prostate protrusion (IPP) versus middle lobe volume on ultrasonography in assessing the impact of benign prostatic hyperplasia. Open J Radiol 2020;10:193-202.

33. Oesterling JE. Benign prostatic hyperplasia: A review of its histogenesis and natural history. Prostate Suppl 1996;6:67-73.

34. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.

35. Oshagbemi AO, Ofoha CG, Akpayak IC, Shuaibu SI,

Dakum NK, Ramyil VM. The predictive value of intravesical

Journal of the West African College of Surgeons | Volume 13 | Issue 2 | April‑June 2023 21

[Downloaded free from http://www.jwacs-jcoac.com on Monday, April 17, 2023, IP: 2.27.163.176]

Okedere, *et al.*: Ultrasonographic intravesical prostatic protrusion in men with benign prostatic hyperplasia in Southwest Nigeria

prostatic protrusion on the outcome of trial without catheter in patients with acute urinary retention from benign prostatic hyperplasia at jos university teaching hospital, Nigeria: A prospective observational study. Pan Afr Med J 2022;42:246.

36. Sigdel G, Belokar WK. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic hyperplasia. J Univers Coll Med Sci 2015;3:6-10.

37. Gopinath V, Palliyani J. Correlation between intravesical prostatic protrusion and prostate volume in patients presenting with acute urinary retention - A descriptive study. MedPulse Int J Surg 2020;17:23-6.

38. Eze BU, Mbaeri TU, Oranusi KC, Abiahu JA, Nwofor AM, Orakwe JC, *et al*. Correlation between intravesical prostatic protrusion and international prostate symptom score among nigerian men with benign prostatic hyperplasia. Niger J Clin

Pract 2019;22:454-9.

39. Shrestha A, Chalise P, Sharma U, Gyawali P, Shrestha G, Joshi B. Intravesical prostatic protrusion is better than prostate volume in predicting symptom severity in benign prostatic hyperplasia: A prospective clinical study. Postgrad Med J NAMS 2010;10:24-8.

40. Wang D, Huang H, Law YM, Foo KT. Relationships between prostatic volume and intravesical prostatic protrusion on transabdominal ultrasound and benign prostatic obstruction in patients with lower urinary tract symptoms. Ann Acad Med Singap 2015;44:60-5.

41. Reddy SVK, ShaikAB. Non-invasive evaluation of bladder outlet obstruction in benign prostatic hyperplasia: A clinical correlation study. Arab J Urol 2019;17:259-64.

42. Lee A, Lee HJ, Lim KB, Huang HH, Ho H, Foo KT. Can intravesical prostatic protrusion predict bladder outlet obstruction even in men with good flow? Asian J Urol

2016;3:39-43.

22 Journal of the West African College of Surgeons | Volume 13 | Issue 2 | April‑June 2023